Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate HELP Leaders Harkin, Alexander Start Year With Teamwork

This article was originally published in The Tan Sheet

Executive Summary

Sen. Lamar Alexander becomes top Republican on the Health, Education, Labor and Pensions Committee, where all four new members are freshmen. HELP Chairman Tom Harkin says this is his last Senate term. The House Energy and Commerce Committee roster also is set.

You may also be interested in...

Harkin Exit Intensifies Industry Need To Bolster Supplement Caucus

One of DSHEA’s chief authors, Tom Harkin will retire from the Senate after 2014, pressuring supplement industry leaders to identify the next generation of congressional supporters. CRN’s Steve Mister says it will not be possible to replace the duo of Harkin and Orrin Hatch, who is retiring after 2018.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts